Ovid Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Ovid Therapeutics
OVID Stock  USD 1.09  0.01  0.91%   
Ovid Therapeutics financial statements provide useful quarterly and yearly information to potential Ovid Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Ovid Therapeutics financial statements helps investors assess Ovid Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Ovid Therapeutics' valuation are summarized below:
Gross Profit
1.5 M
Market Capitalization
78.1 M
Enterprise Value Revenue
48.2414
Revenue
631.7 K
Earnings Share
(0.46)
There are over one hundred nineteen available trending fundamental ratios for Ovid Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to check out all of Ovid Therapeutics' recent performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. As of November 26, 2024, Market Cap is expected to decline to about 132.9 M. In addition to that, Enterprise Value is expected to decline to about 108.5 M

Ovid Therapeutics Total Revenue

372,110

Check Ovid Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ovid Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 3.3 M, Selling General Administrative of 22.5 M or Total Revenue of 372.1 K, as well as many indicators such as Price To Sales Ratio of 609, Dividend Yield of 0.0 or PTB Ratio of 3.82. Ovid financial statements analysis is a perfect complement when working with Ovid Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Ovid Therapeutics Correlation against competitors.
For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.

Ovid Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets100.8 M144 M69.1 M
Slightly volatile
Total Current Liabilities9.6 M11.5 M6.5 M
Slightly volatile
Total Stockholder Equity83.4 M87.8 M57.3 M
Slightly volatile
Net Tangible Assets81.7 M152.1 M61.4 M
Slightly volatile
Accounts Payable3.2 M3.7 M2.2 M
Slightly volatile
Cash25.7 M27 M50.2 M
Slightly volatile
Common Stock Shares Outstanding44 M70.6 M32.3 M
Slightly volatile
Total Liabilities59 M56.2 M14.5 M
Slightly volatile
Total Current Assets93.1 M109.6 M63.9 M
Slightly volatile
Intangible Assets235.2 K183 K158.9 K
Slightly volatile
Common Stock47.4 K70.7 K37.2 K
Slightly volatile
Property Plant Equipment1.4 M1.3 M300.2 K
Slightly volatile
Other Current Liabilities6.6 M6.5 M4.6 M
Slightly volatile
Property Plant And Equipment Net15.4 M14.7 M3.1 M
Slightly volatile
Non Current Assets Total36.2 M34.4 M7.1 M
Slightly volatile
Non Currrent Assets Other25.3 K26.6 K636.3 K
Slightly volatile
Cash And Short Term Investments100.5 M105.8 M84.8 M
Slightly volatile
Net Receivables403.4 K300.4 K270.6 K
Slightly volatile
Common Stock Total Equity46.7 K81 K34.5 K
Slightly volatile
Liabilities And Stockholders Equity111.4 M144 M91.6 M
Slightly volatile
Other Current Assets2.2 M3.8 M1.5 M
Slightly volatile
Other Stockholder Equity276.7 M365.6 M196.5 M
Slightly volatile
Property Plant And Equipment Gross16.4 M15.7 M3.3 M
Slightly volatile
Capital Surpluse312.6 M411.4 M247.9 M
Slightly volatile
Net Invested Capital99.9 M87.8 M88 M
Pretty Stable
Net Working Capital100.3 M98.1 M87.8 M
Slightly volatile
Capital Stock65.4 K70.7 K41.3 K
Slightly volatile
Other Liabilities12.4 M11.8 M3.8 M
Slightly volatile
Non Current Liabilities Other36.2 M34.5 M8.9 M
Slightly volatile
Current Deferred Revenue1.8 M2 M2.2 M
Slightly volatile
Short and Long Term Debt Total13 M16 M16.3 M
Slightly volatile
Short Term Debt979 K1.2 M611.1 K
Slightly volatile

Ovid Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative22.5 M31.1 M15.2 M
Slightly volatile
Research Development33.6 M28.6 M22.7 M
Slightly volatile
Total Operating Expenses56.2 M59.7 M37.9 M
Slightly volatile
Interest Income5.9 M5.6 M1.9 M
Slightly volatile
Depreciation And Amortization1.7 M1.6 M386.8 K
Slightly volatile
Other Operating Expenses62.3 M59.7 M42.6 M
Slightly volatile
Net Interest Income5.9 M5.6 M1.9 M
Slightly volatile
Reconciled Depreciation1.7 M1.6 M421.1 K
Slightly volatile
Non Operating Income Net Other957.3 K1.6 M679.5 K
Slightly volatile
Selling And Marketing Expenses581653711
Slightly volatile

Ovid Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock154.5 K162.6 K21.6 M
Very volatile
Net Borrowings64 K72 K78.4 K
Slightly volatile
Depreciation1.7 M1.6 M383.7 K
Slightly volatile
Capital Expenditures130.6 K137.5 K211 K
Slightly volatile
End Period Cash Flow27.5 M29 M45.1 M
Slightly volatile
Change To Netincome8.9 M7.5 M6 M
Slightly volatile
Stock Based Compensation6.1 M7.3 M4.2 M
Slightly volatile
Begin Period Cash Flow73.2 M44.9 M46.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio60958093.0249
Slightly volatile
PTB Ratio3.822.58865.8459
Slightly volatile
Days Sales Outstanding3.283.694.0189
Slightly volatile
Book Value Per Share2.331.24391.8339
Pretty Stable
Average Payables2.1 M3.2 M2.2 M
Slightly volatile
Stock Based Compensation To Revenue19.5318.59913.2718
Slightly volatile
Capex To Depreciation0.08180.08611.285
Pretty Stable
PB Ratio3.822.58865.8459
Slightly volatile
EV To Sales58055279.9371
Slightly volatile
Inventory Turnover0.180.210.2278
Slightly volatile
Days Of Inventory On Hand1.3 K1.4 K1.5 K
Slightly volatile
Payables Turnover0.670.640.2506
Slightly volatile
Sales General And Administrative To Revenue83.3379.360914.0771
Slightly volatile
Average Inventory97.1 K109.2 K118.9 K
Slightly volatile
Research And Ddevelopement To Revenue76.6372.985114.7674
Slightly volatile
Capex To Revenue0.260.35090.1264
Slightly volatile
Cash Per Share2.631.49952.0422
Slightly volatile
Days Payables Outstanding56459310.4 K
Slightly volatile
Income Quality0.60.87470.6959
Slightly volatile
Intangibles To Total Assets0.00210.00130.002
Slightly volatile
Current Ratio17.259.551622.3799
Slightly volatile
Tangible Book Value Per Share2.321.24131.8294
Pretty Stable
Receivables Turnover71.280.187.2219
Slightly volatile
Graham Number8.434.55576.0547
Slightly volatile
Shareholders Equity Per Share2.331.24391.8339
Pretty Stable
Capex Per Share0.00190.00190.0047
Slightly volatile
Graham Net Net0.670.70281.6953
Very volatile
Average Receivables60.6 K63.8 K160.7 K
Pretty Stable
Revenue Per Share0.00530.00550.3663
Pretty Stable
Price Book Value Ratio3.822.58865.8459
Slightly volatile
Days Of Payables Outstanding56459310.4 K
Slightly volatile
Ebt Per Ebit1.080.88290.9918
Pretty Stable
Company Equity Multiplier0.981.64051.1538
Slightly volatile
Quick Ratio17.249.551622.3749
Slightly volatile
Net Income Per E B T1.081.090.9937
Slightly volatile
Cash Ratio2.242.356720.5211
Slightly volatile
Days Of Inventory Outstanding1.3 K1.4 K1.5 K
Slightly volatile
Days Of Sales Outstanding3.283.694.0189
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.811.0030.9942
Slightly volatile
Price To Book Ratio3.822.58865.8459
Slightly volatile
Fixed Asset Turnover0.02540.0267125
Very volatile
Price Sales Ratio60958093.0249
Slightly volatile
Asset Turnover0.00260.00270.1943
Very volatile
Gross Profit Margin0.06450.07260.079
Slightly volatile
Price Fair Value3.822.58865.8459
Slightly volatile

Ovid Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap132.9 M227.3 M135.2 M
Slightly volatile
Enterprise Value108.5 M216.2 M87.2 M
Pretty Stable

Ovid Fundamental Market Drivers

Forward Price Earnings1.7918
Cash And Short Term Investments105.8 M

Ovid Upcoming Events

11th of March 2024
Upcoming Quarterly Report
View
3rd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
11th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Ovid Therapeutics Financial Statements

Ovid Therapeutics stakeholders use historical fundamental indicators, such as Ovid Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Ovid Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ovid Therapeutics' assets and liabilities are reflected in the revenues and expenses on Ovid Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ovid Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2 M1.8 M
Total Revenue391.7 K372.1 K
Cost Of Revenue1.6 M1.7 M
Stock Based Compensation To Revenue 18.60  19.53 
Sales General And Administrative To Revenue 79.36  83.33 
Research And Ddevelopement To Revenue 72.99  76.63 
Capex To Revenue 0.35  0.26 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(151.35)(143.78)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America
When determining whether Ovid Therapeutics is a strong investment it is important to analyze Ovid Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ovid Therapeutics' future performance. For an informed investment choice regarding Ovid Stock, refer to the following important reports:
How To Invest In Ovid
Details
Is Ovid Stock a good investment?
Details
What is Ovid Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Ovid Therapeutics Correlation against competitors.
For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.
You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ovid Therapeutics. If investors know Ovid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ovid Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.46)
Revenue Per Share
0.009
Quarterly Revenue Growth
0.587
Return On Assets
(0.36)
Return On Equity
(0.37)
The market value of Ovid Therapeutics is measured differently than its book value, which is the value of Ovid that is recorded on the company's balance sheet. Investors also form their own opinion of Ovid Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Ovid Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ovid Therapeutics' market value can be influenced by many factors that don't directly affect Ovid Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Ovid Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ovid Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY